
Opinion|Videos|June 19, 2024
Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates
The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- Could you discuss disease modifying and other therapies for Alzheimer disease that are currently in development?
Advertisement
Related to this article

The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.

A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.

A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.

A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.

Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.

2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.

Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
FDA Approves First Heart Valve to Keep Pace With Children's Growth
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5


